Teva Pharmaceutical and IBM collaborate on Watson Health Cloud

The partnership will enable the pharmaceutical firm to access IBM’s Watson Health Cloud to benefit patients and healthcare providers.

IBM’s Watson is the first commercially available cognitive computing platform that can process natural language queries and huge amounts of data.

Teva intends to use the platform to design treatments for unmet and emerging patients needs including people who suffer from chronic conditions like asthma, pain, migraine and neurodegenerative diseases.

The pharmaceutical firm will work with the technology giant on long-range platform and solutions development.

Experts will collaborate to improve IBM Watson Health Cloud capabilities and identify synergies with existing Watson Health ecosystem partners.

Teva intends to develop solutions designed for collecting and analyzing real world evidence. Plans also include drawing powerful insights and undertaking several initiatives like reducing drug misuse or increasing prescribed medication adherence.

The two companies will also create a joint Teva-IBM research team that will use big data to create disease models and advanced therapeutic solutions.

Teva Pharmaceutical Industries SVP and CIO Guy Hadari said: "By building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best information and insights in the hands of physicians, care teams and patients, to empower treatment optimization for individuals and populations across the spectrum of acute and chronic conditions."